Russia's COVID-19 Vaccine Reports 92% Effectiveness

The effectiveness of the Sputnik V vaccine candidate was found to be 92% based on the distribution of 20 confirmed cases identified in the placebo group and in the group receiving the vaccine candidate. And, the efficacy was proven based on the first interim data analysis 21-days after the study volunteers received their first immunization, reported NITsEM them. N.F. Gamaleis of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund, on November 11, 2020.

Currently, 20,000 volunteers are taking part in a Phase III, double-blind, randomized, placebo-controlled clinical trial of the Sputnik V vaccine and more than 16,000 volunteers have received the first and second doses of the vaccine candidate.

Alexander Gintsburg, Director of the N.N. N.F. Gamalei, stated in a press release: “Scaling up production and connecting new production sites will make the Sputnik V vaccine available to the general public. This will make it possible to reverse the current trend and achieve a decrease in the incidence of coronavirus infection, first in Russia, and then throughout the world."